US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

US biotech Iovance Biotherapeutics is cutting 19% of its workforce due to slower-than-expected launch of its ...

The cancer immunotherapy market is bracing for its next growth phase as bispecific T-cell engagers gain momentum, according ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

German family-owned pharma major Boehringer Ingelheim and New York-based Click Therapeutics today announced that the pivotal ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

US clinical-stage biotech Keros Therapeutics has announced a strategic realignment designed to reallocate resources towards ...

Shares in Gilead Sciences were a massive 9% higher in Friday’s early trading after the US biotech major lifted its full-year financial guidance.

India’s pharmaceutical sector continues to assert its dominance on the global stage, driven by a surge in generic drug launches that are reshaping access to affordable healthcare. A flurry of filings ...

A Californian company developing new treatments to help organ transplant patients keep their transplanted organs healthy over the long term.